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ABSTRACT
Diabetic kidney disease (DKD) is common in Malaysia. Vitamin K deficiency among DKD patients may be associated 
with higher incidence of chronic kidney disease-mineral bone disorder (CKD-MBD).  This study was conducted to 
determine the prevalence of vitamin K deficiency in diabetic patients with CKD stage 3-5. We also correlated vitamin K 
deficiency with baseline demographic, biochemical results and analysed the effects of vitamin K levels on CKD-MBD. 
This was a single centre cross-sectional study on diabetic patients with CKD stage 3-5. Demographic profiles were 
recorded, blood samples were measured for vitamin K level (phylloquinone, proteins induced by vitamin K absence II 
(PIVKA-II), prothrombin time) and bone markers (parathyroid hormone (PTH), alkaline phosphatase, corrected 
calcium and phosphate). This study was approved by UKM ethic and research committee (FF-2018-375). Forty-five 
patients with a median age of 70 (IQR:13) years were recruited.  Majority were females (53.3%) and Malays (64.4%). 
Prevalence of patients with insufficient vitamin K was 28.9 % based on the low level of phylloquinone (<0.4 nmol/L), 
93.3% based on high PIVKA-II level (>0.66 ng/mL) and 2.2% based on prolonged prothrombin time (>14.5 s). PIVKA-
II was found to be positively correlated with serum creatinine and PTH levels. There were positive correlations between 
phylloquinone with serum triglyceride and total cholesterol. Prothrombin time was found to be negatively correlated 
with corrected calcium and total cholesterol. Malay race (p = 0.039) and high serum PTH (p = 0.016) were significantly 
associated with higher PIVKA-II concentrations. Multivariable analysis showed serum triglyceride (OR 0.112; CI 95 
% (0.02-0.66); p = 0.017) and serum PTH (OR 1.997; CI 95 % (1.01-3.95); p = 0.047) were independent predictors for 
abnormal phylloquinone and PIVKA-II levels, respectively. In conclusion, the prevalence of Vitamin K deficiency was 
high in diabetic patients with CKD stage 3-5. Serum triglyceride and serum PTH were independent predictor of Vitamin 
K deficiency.
Keywords: Chronic kidney disease-mineral bone disease; diabetic kidney disease; phylloquinone; protein induced by 
vitamin K absence II (PIVKA II); prothrombin time 
ABSTRAK
Penyakit ginjal yang disebabkan oleh kencing manis (DKD) sangat kerap berlaku di Malaysia. Kekurangan vitamin K 
dalam kalangan pesakit DKD mungkin berhubung kait dengan kejadian penyakit ginjal kronik-gangguan mineral 
tulang (CKD-MBD) yang tinggi. Kajian ini dijalankan untuk menentukan kelaziman kekurangan vitamin K pada pesakit 
DKD tahap 3-5. Kami juga mengkaji hubung kait kekurangan vitamin K dengan demografi dan biokimia asas dan 
menganalisis kesan paras vitamin K pada CKD-MBD. Ini adalah satu kajian rentas pada pesakit DKD tahap 3-5. Profil 
demografi direkodkan, sampel darah diambil untuk tahap vitamin K (filokuinon, proteins teraruh dengan ketiadaan 
vitamin K II (PIVKA-II), tempoh protrombin) dan penanda penyakit CKD-MBD (hormon paratiroid (PTH), fosfatase 
beralkasi, kalsium dan fosfat). Kajian ini telah diluluskan oleh Jawatankuasa Etika dan Penyelidikan UKM (FF-2018-
375). Empat puluh lima pesakit dengan umur median 70 (IQR: 13) tahun telah direkrut. Majoriti adalah perempuan 
(53.3 %) dan Melayu (64.4 %). Peratusan pesakit dengan kekurangan vitamin K adalah 28.9 % berdasarkan tahap 
rendah filokuinon (<0.4 nmol/L), 93.3 % berdasarkan tahap PIVKA-II yang tinggi (> 0.66 ng/mL) dan 2.2 % berdasarkan 
masa protrombin yang berpanjangan (> 14.5 saat). PIVKA-II didapati mempunyai kaitan positif dengan nilai serum 
kreatinin dan PTH. Terdapat hubung kait positif antara filokuinon dengan serum trigliserida dan kolesterol. Tempoh 
protrombin didapati berhubung kait secara negatif dengan kalsium dan tahap kolesterol. Bangsa Melayu (p = 0.039) 
dan serum tinggi PTH (p = 0.016) adalah berkaitan dengan kepekatan PIVKA-II. Analisis pelbagai pemboleh ubah 
menunjukkan trigliserida serum (OR 0.112; CI 95% (0.02-0.66); p = 0.017) dan tahap PTH (OR 1.997; CI 95% (1.01-
3.95); p = 0.047) adalah peramal untuk keabnormalan filokuinon dan tahap PIVKA-II . Kesimpulannya, kekurangan 
vitamin K kerap berlaku pada pesakit diabetes dengan CKD tahap 3-5. Serum trigliserida dan serum PTH adalah 
peramal bebas kekurangan vitamin K.
Kata kunci: Filokuinon; penyakit buah pinggang diabetes; penyakit ginjal kronik - penyakit mineral tulang; protein 
teraruh dengan ketiadaan vitamin K II (PIVKA II); tempoh protrombin
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INTRODUCTION
There has been an increasing prevalence of diabetic kidney 
disease (DKD) in Malaysia and worldwide. DKD is the 
main cause for ESRD in developed countries ranging from 
30 - 45 % of all cases and also developing countries ranging 
from 30 - 60 % of all cases (Ghaderian et al. 2015). 
Similarly in Malaysia, DKD is the leading cause of renal 
failure for patients initiating dialysis, increasing from 53 
% in 2004 to 61 % in 2013 (Goh et al. 2014). The 
prevalence of patients with end stage renal disease (ESRD) 
on dialysis in Malaysia has increased from 629 per million 
population in 2007 to 1286 per million population in 2016 
(Bujang et al. 2017). This markedly increasing number of 
ESRD plays an enormous role on human, economic and 
social burden on our healthcare system. 
Patients with DKD has an increased risk for 
cardiovascular and mineral bone disease. The Clinical 
Practice Guidelines by The Kidney Disease Improving 
Global Outcomes (KDIGO) recommends screening 
patients for the presence of vascular calcification which 
leads to major complications of the disease (KDIGO 2009) 
Chronic kidney disease-mineral and bone disorder (CKD-
MBD) is a systemic disorder impairing the metabolism of 
bone and minerals in the body via abnormal mineralization 
and bone turnover which results from impaired calcium, 
phosphate, parathyroid hormone (PTH) and vitamin D 
metabolism. Mineral metabolism disorders and 
dysregulation of endocrine function may result in renal 
bone disease along with skeletal and extra skeletal 
complications. Patients with CKD-MBD has higher 
incidences of vascular calcifications, cardiovascular 
disease and lower bone mineral contents as the disease 
progresses (Klawansky et al. 2003). Factors like 
hyperphosphatemia, vitamin D deficiency, chronic 
inflammation, increased calcium load may promote 
calcification (Cozzolino et al. 2019). 
Vitamin K is a fat-soluble vitamin which acts as a 
co-factor for the enzyme γ-glutamyl carboxylase (GGCX). 
It is needed for the activation of vitamin K-dependent 
proteins (VKDPs) which involved in hemostasis as well 
as vascular and bone health (Berkner & Runge 2004). 
VKDPs which are the osteocalcin and matrix GLA protein 
protects from bone fractures and cardiovascular 
calcifications, respectively. Vitamin K recycling system 
helps to maintain a sufficient level of vitamin K for 
activation of VKDPs through GGCX (Berkner & Runge 
2004).
Two forms of vitamin K, which are available can be 
found in green vegetables known as K1 or phylloquinone, 
and K 2 or menaquinones, found in specific food (such as 
natto, in Japan) or derived from the metabolic activity of 
intestinal bacteria (Booth & Al Rajabi 2008). An important 
cause for vitamin K deficiency in CKD patients is reduction 
of  dietary intake due to patient’s uremic symptoms. It has 
been shown that an adequate amount of vitamin K intake 
may help to prevent bone mineral disorders and vascular 
calcifications (Kaesler et al. 2014).
CKD patients with vitamin K deficiency had higher 
incidence of cardiovascular disease and bone fractures 
among the American and Canadian populations in a review 
by McCabe et al. (2013). Liver is the site of synthesis of 
vitamin K dependent coagulation factors and is the major 
site of storage of vitamin K. Storage of vitamin K can be 
evaluated by the direct measurement of circulating Vitamin 
K1 (Booth & Al Rajabi 2008). Vitamin K deficiency can 
be analysed via markers such as phylloquinone level (< 
0.4 nmol/L), proteins induced by vitamin K absence 
(PIVKA-II) (>2 nmol/L) (Elliott et al. 2014) and prolonged 
prothrombin time (PT) (Quick 1975).
In a study conducted by Holden et al. (2010) among 
172 stage 3 to 5 CKD patients, more than 50% of them 
consumed less than the recommended adequate intake of 
vitamin K which was monitored with serum phylloquinone 
level, osteocalcin and protein induced by vitamin K 
absence (PIVKA-II). It was concluded that lower dietary 
intake of vitamin K predicted lower levels of phylloquinone 
(6% insufficient) and higher levels of PIVKA-II (97% 
insufficient). A study done by Kohlmeier et al. (1997) 
showed that patients with fractures and hyperparathyroidism 
were more severe in patients with poor vitamin K status. 
Patients with low phylloquinone concentrations had 
severely elevated PTH concentrations. The correlation 
between vitamin K and PTH concentrations suggests that 
a vitamin K-dependent process is important for the 
regulation of parathyroid hormone.
We hypothesize that Vitamin K deficiency is common 
in diabetic patients with CKD stage 3-5 and is associated 
with higher incidence of CKD-MBD. Thus, we embarked 
on this study to determine the prevalence of vitamin K 
deficiency in diabetic patients with CKD stage 3-5 patients 
and study its correlation with CKD-MBD. 
MATERIALS AND METHODS
This was a single centre cross-sectional study involving 
diabetic patients with CKD stage 3-5 receiving nephrology 
care at Hospital Canselor Tuanku Muhriz (HCTM), 
Universiti Kebangsaan Malaysia Medical Centre. This 
study was approved by UKM Ethic and Research 
Committee (FF-2018-375). We included diabetic patients 
with CKD stages 3-5 who were more than 18 years old 
and not on warfarin or novel oral anticoagulants treatment. 
Our exclusion criteria included patients on renal 
replacement therapy, vitamin K supplement for the last 3 
months, history of malignancy tumour disease and alcohol 
or drug abuse, malabsorption syndromes, chronic liver 
disease, mental condition rendering the subject unable to 
understand the nature, scope and possible consequences 
of the study, pregnant and lactating patients, chronic 
infection, participation in any previous trial on vitamin K, 
history of non-compliance and unable to provide signed 
informed consent. Diabetic patients with CKD stage 3-5 
(stage 3 eGFR 30-59 mL/min/1.73 m2, stage 4 eGFR 15-29 
mL/min/1.73 m2, stage 5 eGFR less than 15 mL/min/1.73 
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m2 non dialysis) under the nephrology clinic follow up 
were enrolled after initial screening. For estimation of 
Glomerular Filtration Rate (eGFR), Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation 
was used (Levey et al. 2009). Venous blood were collected 
for measurement of vitamin K level (phylloquinone, 
PIVKA-II, PT) and CKD-MBD markers (PTH, alkaline 
phosphatase, corrected calcium and phosphate).
Vitamin K1 can be measured using a modified high-
performance liquid chromatography (HPLC) method and 
fluorescence detection (Azharuddin et al. 2007). HPLC 
with fluorescence detection has shown greater sensitivity 
and selectivity compared to UV detection but extensive 
sample pre-purification is required to reduce the 
chromatographic interference induced by lipid. Detection 
of human Vitamin K1 using Enzyme-Linked Immuno-
sorbent Assay (ELISA) method has high sensitivity and 
specificity (Vitamin K1, Amsbio).
Serum PIVKA-II is determined using a monoclonal 
antibody to PIVKA-II in an ELISA (Belle et al. 1995) This 
assay has high sensitivity and excellent specificity for 
detection of human PIVKA-II and no significant cross-
reactivity or interference between human PIVKA-II and 
analogues were observed (PIVKA-II, Amsbio).
Serum for phylloquinone and PIVKA II assays were 
centrifuged at 3000 rpm for 15 min at room temperature 
and stored at -80 °C before the analysis. Serum 
phylloquinone and PIVKA II were measured in duplicates 
using sandwich enzyme immunoassay technique, in a 
single laboratory and was assayed in a single batch to avoid 
inter assay variations. Phylloquinone were measured using 
Human Vitamin K1 ELISA technique (AMS Biotechnology 
(Europe) Limited, UK). Phylloquinone level (normal range 
0.4-3.44 nmol/L) evaluate storage of vitamin K and 
nutritional status. A low level of phylloquinone (< 0.4 
nmol/L) indicates vitamin K deficiency (Elliot et al 2014). 
PIVKA II concentration (normal range 0.4 - 0.66 ng/
mL) were determined by using commercially available kits 
from AMS Biotechnology which uses Human PIVKA II 
ELISA technique. PIVKA II is an early marker of 
subclinical vitamin K deficiency. A raised PIVKA II level 
(> 0.66 ng/mL) indicates vitamin K deficiency (Elliot et 
al 2014). PT is an indirect marker of vitamin K deficiency. 
Prolonged PT (more than 14.5 s) indicates vitamin K 
deficiency (Quick 1975). PT, corrected calcium, PTH, 
alkaline phosphatase, and phosphate samples were 
measured using routine methods available in our centre.
STATISTICAL ANALYSES
Data were analysed using the Statistical Package for Social 
Science (SPSS) software version 25. Normally distributed 
data were expressed as mean ± standard deviation (SD) 
and non-normally distributed data were expressed as 
median (IQR). Correlations were tested using Spearman 
correlation coefficients.  For the categorical variables, 
frequencies and percentages were obtained and tabulated. 
Categorical variables were analysed using Chi squared test 
or Fisher’s Exact test as appropriate. The magnitude of 
associations was tested using ratios and confidence 
intervals for the ratios. Multivariate analyses were 
performed using binary logistic regression to determine 
independent predictors of vitamin K status. All statistical 
tests were two sided and an unadjusted p value of < 0.05 
was considered statistically significant.
RESULTS
DEMOGRAPHY
The demographic and clinical details of all the patients are 
shown in Table 1. There were forty-five patients with a 
median age of 70.0 (IQR:13.0) years were recruited. 
Majority were females (53.3%) and Malays (64.4%). Based 
on comorbidities, 82.2% had hypertension, 66.7% had 
dyslipidaemia, 15.6% with ischemic heart disease and 8.9% 
had history of cerebrovascular disease.
PHYLLOQUINONE
Thirteen patients (28.9%) met criteria for vitamin K 
deficiency based on the low level of phylloquinone (<0.4 
nmol/L). Overall median serum phylloquinone 
concentration in 45 patients was 0.53(IQR:0.72) nmol/L 
(Table 1). There were positive correlations between 
phylloquinone and serum triglyceride (p = 0.002) and total 
cholesterol (p = 0.006) (Table 2). High serum triglyceride 
(OR 8.06; CI 95% (1.52-41.7); p = 0.007) and total 
cholesterol (8.12; CI 95% (1.02-71.4); p < 0.038) levels 
were strongly associated with higher phylloquinone 
concentrations. We found no strong correlation and 
significant association between phylloquinone 
concentration and CKD-MBD markers (PTH, alkaline 
phosphatase, corrected calcium and phosphate) (Table 3). 
The single independent predictor of abnormal phylloquinone 
concentration was serum triglycerides (OR 0.112; CI 95% 
(0.02-0.66); p = 0.017) (Table 4).
PROTEINS INDUCED BY VITAMIN K ABSENCE II      
(PIVKA-II)
The median serum PIVKA-II level measured in 45 patients 
was 2.23 (IQR: 1.94) ng/mL. There were 93.3% of patients 
had vitamin K deficiency based on high PIVKA-II level 
>0.66 ng/mL, corresponding to worse vitamin K status 
(Table 1). PIVKA-II was found to be positively correlated 
with serum creatinine (p = 0.032) and PTH (p = 0.005) 
levels (Table 2). Malay race (OR 1.23; CI 95% (1.01-1.56); 
p = 0.039) and high serum PTH (OR 1.33; CI 95 % (1.02 
- 1.85); p = 0.016) were significantly associated with higher 
PIVKA-II concentrations. There was no significant 
correlation between PIVKA II concentration and other 
CKD-BMD markers such as alkaline phosphatase, 
corrected calcium and phosphate (Table 3). The only 
independent predictor of abnormal PIVKA-II concentration 
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TABLE 1. Demographic and clinical features of study population
Variables N (%) Median (IQR) Mean ± SD
Clinical characteristics (n = 45)
Age, years 70 (13)










eGFR, mL/min per 1.73 m2 21.2(21.1)
CKD stage 3 15 (33.3)
CKD stage 4 15 (33.3)
CKD stage 5 15 (33.3)
Comorbidities
Hypertension 37 (82.2)
Cerebrovascular disease 4 (8.9)
Ischemic heart disease 7 (15.6)
Dyslipidemia 30 (66.7)
Vitamin K status
Phylloquinone, nmol/l 13(28.9) * 0.53 (0.72)
PIVKA II, ng/mL 42(93.3) * 2.23 (1.94)
Prothrombin time, (s) 1(2.2) * 13.0 (1.0)
Laboratory measures
Phosphate, mmol/l 1.16 (0.36)
Corrected calcium, mmol/l 2.41 ± 0.12
Serum iPTH, pmol/l 9.8 (8.38)
Serum ALP, u/L 84.0 (39)
Serum Albumin, g/l 36.0 (5)
Serum creatinine, umol/l 231.5 (180.3)
Haemoglobin, g/dl 11.91 ± 1.70
Serum TG, mmol/l 1.84 ± 0.73
Serum TC, mmol/l 4.4 (1.19)
Serum HDL, mmol/l 1.09 ± 0.28
Serum LDL, mmol/l 2.32 (1.34)
Hba1c, % 7.5 (2.75)
*Vitamin K deficiency.  Normally distributed data were expressed as mean ± (SD) and non-normally distributed data were expressed as median (IQR). eGFR, estimated 
glomerular filtration rate; CKD, chronic kidney disease; PIVKA II, proteins induced by vitamin K absence; PTH, parathyroid hormone; ALP, alkaline phosphatase; TG, 
triglycerides; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein
by binary logistic regression was serum PTH (OR 1.997; 
CI 95% (1.01-3.95); p = 0.047) (Table 4).
PROTHROMBIN TIME (PT)
Median PT in 45 patients was 13.0 (1.0) s. Vitamin K 
deficiency criteria defined as > 14.5 s was met in one patient 
(2.2%). PT was found to be negatively correlated with 
corrected calcium (p = 0.048) and total cholesterol (p = 
0.025) levels (Table 2). There were no significant 
associations between prolonged PT and demography, 
comorbidities and laboratory measurements.
DISCUSSION
This was the first local study assessing vitamin K status in 
diabetic patients with CKD stage 3-5 and confirmed that 
these patients have a poor vitamin K status. We found that 
Malay race was significantly associated with higher 
PIVKA-II concentrations that suggested vitamin K 
deficiency. As a multicultural country, each race in 
Malaysia has their own cuisine and  this finding may 
suggest that Malay race did not consume the recommended 
amount of vitamin K. Lower vitamin K intake may be 
related to the dietary restriction recommended in CKD 
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patients which limits intake of sodium and potassium that 
subsequently leads to reduced intake of foods with high 
vitamin K content as supported by other studies (Beto et 
al. 2014; Cranenburg et al. 2012). Hence, a larger local 
study with proper dietary information with food 
questionnaire needed to confirm the present results. There 
were more female in our study as supported by other study 
that showed that diabetic kidney disease was more common 
in female (Abougalambou et al. 2016) and higher risk of 
fracture especially diabetic postmenopausal women 
(Abdulameer et al. 2018). Collins and Cashman (2006) 
and Tsugawa et al. (2006) reported that elderly population 
were more susceptible for lower vitamin K intakes and the 
circulating uncarboxylated osteocalcin concentrations were 
highest in the oldest group that clearly indicates the 
requirement for vitamin K increase with age respectively.
Nevertheless, we did not find any correlation between older 
age and vitamin K deficiency. Our finding is similar with 
a study done by Ikeda et al. (2006) and Yan et al. (2004) 
which demonstrated that older individuals in northern 
China and postmenopausal women in Japan have a better 
vitamin K status due to higher consumption of green 
vegetables and natto. As we know, the incidence of 
osteoporosis related fractures among the older generation 
is very common due to low bone mass and microarchitectural 
deterioration of bone tissue (Khir et al. 2012; Pillai et al. 
2011). Previous study showed that high vitamin K 
consumption was associated with reduced bone loss and 
fracture incidence in elderly people (Cockayne et al. 
2006).
The data of this study showed the prevalence of 
hypertension, dyslipidaemia, ischemic heart disease, 
cerebrovascular disease at 82.2, 66.7, 15.6 and 8.9 %, 
respectively. Hypertension and dyslipidaemia are major 
independent risk factor for the development and progression 
of DKD (Forbes & Cooper 2013). Study has shown the 
combination of low vitamin D and K status was associated 
with increased blood pressure and a trend  for greater 
hypertension risk (van Ballegooijen et al. 2017). The 
prevalence of vitamin K deficiency in CKD patients has 
shown higher incidences of cardiovascular disease and 
vitamin K replacement in CKD patients protect from 
cardiovascular calcifications (Gallieni & Fusaro 2014; 
Krueger et al. 2009). There is no association between intake 
of vitamin K and stroke risk among the cerebrovascular 
disease population (Vissers et al. 2013). A study by Larsson 
et al. (2018) demonstrated that genetically higher 
circulating vitamin K1 levels are associated with an 
increased risk of large artery atherosclerotic stroke.
In our study, vitamin K status was investigated using 
measurements of phylloquinone, PIVKA II and PT. 
Vitamin K insufficiency in diabetic patients with CKD 
stage 3-5 patients was 28.9 % based on low level of 
phylloquinone. Holden et al. (2010) in a study of 172 stage 
3–5 CKD patients, demonstrated that 6% were vitamin 
K-insufficient according to low levels of serum 
phylloquinone. It should be noted, however, that 
phylloquinone was measured with HPLC test whereas in 
our study ELISA technique was used. Their results may, 
therefore, not be comparable with our results. Marinova 
TABLE 2. Spearman Correlations among measures of vitamin K status, demographic and biochemical variables
 Variables Phylloquinone (nmol/l) PIVKA II (ng/mL) Prothrombin time (s)
r p R p r p
Age, years 0.12 0.432 0.00 0.986 0.12 0.439
eGFR, mL/min per 1.73 m2 -0.21 0.421 -0.25 0.100 -0.20 0.178
Phylloquinone (nmol/l) - - 0.09 0.554 -0.22 0.155
PIVKA II (ng/mL) 0.09 0.554 - - -0.11 0.463
Prothrombin time (s) -0.22 0.155 -0.11 0.463 - -
Phosphate (mmol/l) 0.08 0.583 -0.10 0.511 0.02 0.902
Corrected calcium (mmol/l) 0.09 0.572 -0.02 0.897 -0.30 0.048*
Serum PTH (pmol/l) 0.26 0.081 0.42 0.005* 0.04 0.778
Serum ALP (u/l) 0.81 0.243 0.14 0.375 -0.01 0.938
Serum Albumin (g/l) 0.10 0.532 0.22 0.142 -0.24 0.112
Serum Creatinine (umol/l) 0.12 0.448 0.32 0.032* 0.18 0.249
Haemoglobin (g/dl) -0.09 0.545 -0.02 0.886 -0.10 0.518
Serum TG (mmol/l) 0.46 0.002* 0.03 0.833 -0.10   0.529
Serum TC (mmol/l) 0.41 0.006* 0.13 0.382 -0.34 0.025*
Serum HDL (mmol/l) 0.16 0.306 0.10 0.515 -0.13   0.400
Serum LDL (mmol/l) -0.21 0.170 0.02 0.900 -0.13 0.403
Hba1c (%) -0.04 0.798 -0.02 0.886 -0.10 0.512
*Significant correlation P<0.05; CKD, chronic kidney disease; PIVKA II, proteins induced by vitamin K absence; PTH, parathyroid hormone; ALP, alkaline 
phosphatase; TG, triglycerides; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein
TABLE 3. Association between vitamin K status and socio-demographic factors, comorbidities and laboratory measurements (n=45)
Socio-demographic Abnormal Phylloquinone (<0.4 nmol/L) P Abnormal PIVKA II  (>0.66 ng/mL) Abnormal Prothrombin time (>14.5 s)
n (%) OR (95% CI) p n (%) OR (95%CI) p n (%) OR (95%CI) p
Sex
Female 7 (29.2) 0.97(0.27-3.54) 0.965* 22 (91.7) 1.82(0.15-21.62) 0.99 1 (4.2) 0.96(0.88-1.04) 0.99
Male 6 (28.6) 20 (95.2) 0 (0)
Age
Below 65 4 (25.0) 1.4(0.34-5.36) 0.743 15 (93.8) 0.90(0.08-10.77) 0.99 0 (0) 1.04(0.97-1.11) 0.99
65 and above 9 (31) 27 (93.1) 1 (3.4)
Ethnic
Malay 9 (31) 0.74(0.18-2.94) 0.743 29 (100) 1.23(1.01-1.56) 0.039 0 (0) 1.07(0.94-1.21) 0.36
Chinese 4 (25) 13 (81.3) 1 (6.3)
Comorbidities
Hypertension
Yes 9 (24.3) 3.13(0.64-14.29) 0.202 34 (91.9) 0.92 (0.83-1-01) 0.99 1 (2.7) 1.03(0.97-1.08) 0.99
No 4 (50) 8 (100) 0 (0)
CVD
Yes 13 (28.9) 1.23(0.12-12.50) 0.99 3 (75) 6.67(0.45-90.90) 0.249 0 (0) 0.98(0.93-1.02) 0.99
No 12 (29.3) 39 (95.1) 1 (2.4)
IHD
Yes 2 (25) 1.27(0.22-7.14) 0.99 7 (87.5) 2.5(0.20-31.25) 0.452 0 (0) 0.97(0.92-1.03) 0.99
No 11 (29.7) 35 (94.6) 1 (6.7)
Dyslipidaemia
Yes 11 (36.7) 0.27(0.05-1.41) 0.165 29 (36.7) 0.22(0.02-2.70) 0.254 0 (0) 0.97 (0.82-1.07) 0.33
No 2 (13.3) 13 (86.7) 1 (6.7)
Vitamin K status
Phylloquinone
Abnormal (low) - - - 12 (92.3) 1.25(0.10-14.29) 0.99 0(0) 1.03(0.97-1.10) 0.99
Normal - - - 30 (93.8) 1(3.1)
PIVKA II
Abnormal (high) 12 (28.6) 1.25 (0.10-14.29) 0.99 - - - 0(0) 1.49(0.68-3.33) 0.07
Normal 1 (33.3) - - - 1(33.3)
Prothrombin time
Abnormal (prolonged) 13 (29.5) 0.71 (0.58-0.85) 0.99 0 (0) 20(5.56-8.33) 0.067 - - -
Normal 0 (0) 42 (95.5) - - -
Laboratory measures
Phosphate, mmol/l
Abnormal (High) 0 (0) 1.47 (1.19-1.82) 0.308 4 (100) 1.08(0.99-1.18) 0.99 0(0) 1.02(0.98-1.08) 0.99
Normal 13 (31.7) 38 (92.7) 1(2.4)
Calcium, mmol/l
Abnormal (Low) 0 (0) 1.41 (1.18-1.72) 0.99 0 (0) 1.08(0.99-1.16) 0.99 0(0) 1.02(0.98-0.08) 0.99
Normal 13 (29.5) 41 (93.2) 1(2.3)
Serum PTH, pmol/l
Abnormal (High) 9 (27.3) 1.33 (0.32-5.56) 0.721 33(100) 1.33(1.02-1.85) 0.016 0(0) 1.08(0.92-1.30) 0.25
Normal 4 (33.3) 9(75) 1(8.3)
Serum ALP, u/l
Abnormal (High) 1 (33.3) 0.88 (0.07-10.00) 0.99 3(100) 1.08(0.99-1.18) 0.99 0(0) 1.02(0.98-1.08) 0.99
Normal 12 (28.6) 39(92.9) 1(2.4)
Serum Albumin, g/l
Abnormal (low) 6 (40) 2.17(0.57-8.33) 0.304 13(86.7) 0.22(0.02-2.70) 0.254 0(0) 0.97(0.89-1.03) 0.99
Normal 7 (23.3) 29(96.7) 1(3.3)
Haemoglobin, g/dl
Abnormal (Low) 8 (32) 1.41 (0.38-5.26) 0.607* 24(96) 0.38(0.03-4.47) 0.577 0(0) 0.95(0.86-1.05) 0.44
Normal 5 (25) 18(90) 1(5)
Hba1c, %
Abnormal (High) 10 (30.3) 1.23 (0.29-5.88) 0.99 30(90.9) 1.10(0.99-1.22) 0.553 1(3) 1.03(0.97-1.10) 0.99
Normal 3 (25) 12(100) 0(0)
Serum TC, mmol/l
Abnormal (high) 1 (7.1) 8.19 (1.02-71.43) 0.038 14(100) 1.11(0.99-1.23) 0.541 0(0) 1.03(0.97-1.10) 0.99
Normal 12 (38.7) 28(90.3) 1(3.2)
Serum TG, mmol/l
Abnormal (high) 2 (9.5) 8.06 (1.52-41.67) 0.007* 2(9.5) 0.55(0.05-6.67) 0.99 0(0) 1.04(0.96-1.13) 0.99
Normal 11 (45.8) 22(91.7) 1(4.2)
Serum HDL, mmol/l
Abnormal (low) 12 (34.3) 0.21 (0.02-1.89) 0.238 32(91.4) 0.91(0.83-1.01) 0.99 1(2.9) 0.97(0.91-1.03) 0.99
Normal 1 (10) 10(100) 0(0)
Serum LDL, mmol/l
Abnormal (high) 6 (30) 0.91 (0.25-3.33) 0.883* 19(95) 0.61(0.05-7.14) 0.99 0(0) 1.04(0.96-1.12) 0.99
Normal 7 (28) 23(92) 1(4)
p<0.05 = statistically significant; OR, Odds Ratio; CI, Confidence interval; *Chi squared test; PIVKA II, proteins induced by vitamin K absence; PTH, parathyroid hormone; ALP, alkaline phosphatase; TG, triglycerides; TC, total cholesterol; HDL, high 
density lipoprotein; LDL, low density lipoprotein; CVD, Cerebrovascular disease; IHD, Ischemic heart disease; Calcium; Corrected calcium
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et al. (2011) reported on recognition of a highly sensitive 
and reliable HPLC method for the determination of vitamin 
K serum concentrations. Immunoassays are characterised 
by their high specificity and sensitivity, cost effectiveness 
and capability of detecting the low concentration of 
residues which makes it useful for routine uses (Zhang et 
al. 2018). Detection of serum vitamin K1 and PIVKA II 
using ELISA method has high sensitivity and specificity 
with no significant cross-reactivity between  analogues 
were observed (Vitamin K1, Amsbio; PIVKA-II, Amsbio). 
However, there is no study done on development of 
multianalyte techniques for detection of vitamin K in a 
single analytical run. Individuals with DKD have 
significantly lower phylloquinone concentrations (median 
0.53 IQR: 0.72) nmol/L (range 0.17-5.12 nmol/L) than 
previously reported individuals with stage 3 to 5 CKD 
(mean: 2.1 ± 2.4 nmol/L range 0-19.3 mol/L) (Holden et 
al. 2010). DKD patients need more requirement of 
vitamin K to form carboxylation of osteocalcin which is 
necessary and important for glucose metabolism. 
Previous study by Chen et al. (2013) showed patients 
with DKD have an imbalance of bone mineral metabolism 
with reduced level of serum osteocalcin and bone mineral 
density. We found a strong correlation and association 
between phylloquinone concentration with total 
cholesterol and triglycerides. There was a strong 
independent connection between triglyceride and 
phylloquinone level. Triacylglycerol-rich lipoproteins 
transports vitamin K in the circulation in both postprandial 
and fasting state (Lamon-Fava et al. 1998). It shows that 
dietary intake influence circulating phylloquinone which 
concludes that patients who are clinically well nourished 
have better vitamin K status, as reported in previous study 
(Elliott et al. 2014; Holden et al. 2010). Although it is 
expected that overall decreased dietary intake and 
subsequent malnutrition is a possible mechanism for 
suboptimal vitamin K status in this population, we could 
not find any association between serum albumin and 
phylloquinone at the moment. 
Dietary and non-dietary factors affects the 
phylloquinone concentration. However, in our study, we 
did not determine non-dietary factors such as apolipoprotein 
E (apoE) genotype which is essential for vitamin K 
mobilization to peripheral tissues (Newman et al. 2002). 
High uptake of triglyceride-bound vitamin K in the liver 
renders a low vitamin K delivery to the tissues (Pilkey et 
al. 2007). The low phylloquinone concentrations observed 
in our study is postulated as a consequence of low vitamin 
K consumption.
PT is a classical method to identify vitamin K 
deficiency. PT acts as an indicator of vitamin K status, 
however, there must be approximately a 50 % decrease 
in prothrombin before the prothrombin time becomes 
abnormal. In our study, only 2.2 % having prolonged PT. 
Based on this, we can conclude that PT greatly 
underestimate the actual incidence of vitamin K 
deficiency and not a good surrogate marker to identify 
vitamin K deficiency (Sokoll & Sadowski 1996). Calcium 
works together with vitamin K in clotting cascade. 
Inadequate calcium level may have impaired haemostasis 
function. We found similar correlation between PT and 
corrected calcium, but so far this relationship has not 
been reported. It has been shown that patients with 
hypercholesterolemia have non prolonged PT value than 
patients with lower cholesterol level (Kim et al. 2015). 
An elevation of procoagulant factors may contribute to 
short PT value in subjects with raised blood lipids which 
is implicated in our study.
In this present study, majority of patients (93.3%) had 
elevated PIVKA-II concentrations, confirming that hepatic 
and peripheral vitamin K status was not adequate to support 
the carboxylation of the VKDPs which are osteocalcin and 
matrix GLA proteins. In our study, higher PIVKA-II 
concentrations were positively correlated with serum 
creatinine and PTH levels. It may suggest worsening renal 
function with low vitamin K level lead to acceleration of 
CKD-MBD. In the current study, we observed serum PTH 
remained significant in multivariable model. The close 
relationship between high PIVKA II and PTH concentrations 
may suggest that vitamin K-dependent proteins are 
important for the regulation of PTH. A study done by Elliott 
et al. (2014) showed PIVKA II may be a good biomarker 
of vitamin K status as its measurement is not influenced 
by kidney function or dyslipidaemia. Kohlmeier et al. 
(1997) demonstrated suboptimal vitamin K in haemodialysis 
patients is associated with increased bone fracture risk and 
high prevalence of hyperparathyroidism. Strong evidence 
on the relationship between PIVKA II and PTH in this 
study showed PIVKA II level has significant effect on 
CKD-MBD makers. The odds to get abnormal PIVKA II 
in patients with elevated PTH is 1.99 times more compared 
to non-elevated level. In addition, our current and previous 
TABLE 4. Independent predictive factor for abnormal vitamin K level in diabetic patients                                                              
with chronic kidney disease stage 3-5
Variable Adjusted odds ratio 95% C.I. for p
Lower Upper
Phylloquinone (R2 = 0.38, n = 45) 
High triglycerides 0.112 0.02 0.66 0.017
PIVKA-II (R2 = 0.45, n = 45)
High PTH 1.997 1.01 3.95 0.047
p<0.05 = statistically significant; PIVKA II, proteins induced by vitamin K absence; PTH, parathyroid hormone
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studies have not demonstrated an association between 
PIVKA II and phylloquinone in patients with CKD stage 
3-5 (Elliott et al. 2014).
The relationship between vitamin K and bone health 
in CKD non dialysis populations has been studied less 
intensely, however, a few studies has been published related 
to vitamin K and effects on CKD-MBD in end stage renal 
disease patients. Fusaro et al. (2012) have recently 
published the results of the vitamin K, vertebral fractures, 
vascular calcifications and mortality which were an 
observational study among 387 haemodialysis patients. 
This study suggests that vitamin K is important in 
preserving bone mass and avoiding vascular calcification 
in haemodialysis patients (Fusaro et al. 2012). Reduced 
vitamin K consumption has been associated with low bone 
mineral density and increased fracture risk in end stage 
renal disease and treatment with vitamin K may reduce the 
risk for hip fractures (Apalset et al. 2011; Evenepoel et al. 
2019). Vitamin K supplementation may become an 
important option in the standard treatment for patients with 
CKD-MBD complications (Krueger et al. 2009).
CONCLUSION
In our study we found that vitamin K deficiency was 
prevalent in diabetic patients with CKD stage 3-5. Serum 
triglyceride and serum PTH were independent predictor 
of Vitamin K deficiency. The main limitation of this study 
is its cross-sectional nature with small sample size and 
lack of measurement of other vitamin K surrogate 
biomarkers indicating the vitamin K status, such as 
dephosphorylated undercarboxylated osteocalcin and 
matrix GLA protein. The mechanism by which vitamin 
K might decrease elevated PTH concentrations and 
protect against bone fracture in CKD-BMD is still not 
known. Therefore, future study should be done to study 
the effect of replacing vitamin K on CKD-MBD in 
vitamin K deficiency CKD patients. 
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